Tysabri and PML: What Clinicians Want You to Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

General Health Context and Tysabri-Associated PML

If you or a loved one takes Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare brain infection is a serious concern, but understanding the evidence can help you have informed discussions with your healthcare provider. The medical community has long recognized the need for balanced information about treatment risks, and this page provides a neutral summary of current clinical knowledge on Tysabri-associated PML.

Medical Evidence: Tysabri and PML Risk

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri highlighting this risk, and the drug is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors increase the likelihood of developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are advised to consider these factors in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For multiple sclerosis patients, an MRI scan should be obtained before starting Tysabri to help differentiate subsequent MS symptoms from PML; for Crohn's disease patients, a baseline brain MRI may also be helpful, though brain lesions at baseline that could cause diagnostic difficulty are uncommon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Prognosis and Treatment for Severe PML After Tysabri

The clinical presentation of PML can include progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis typically relies on brain MRI findings and detection of JCV DNA in cerebrospinal fluid. Because PML can be rapidly progressive, early recognition is critical. The FDA label instructs that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation; therefore, patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least six months after stopping Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prognosis for patients who develop PML after Tysabri treatment is poor. The boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Treatment for severe PML is primarily supportive, focusing on immune reconstitution. In the context of Tysabri-associated PML, the main therapeutic approach is to remove the drug and restore immune function, often through plasma exchange or immunoadsorption to accelerate clearance of natalizumab. However, immune reconstitution can itself lead to an inflammatory reaction known as immune reconstitution inflammatory syndrome (IRIS), which may worsen neurological outcomes. There is no specific antiviral therapy for JCV infection. The timeline between Tysabri exposure and documented harm varies; PML risk increases with cumulative exposure, particularly beyond two years of treatment, but cases have been reported earlier, especially in patients with additional risk factors such as prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML has been a subject of regulatory scrutiny. The FDA requires a boxed warning, a Medication Guide, and enrollment in the TOUCH Prescribing Program, which mandates that prescribers and patients understand the risks. Despite these measures, PML remains a significant concern, and the label emphasizes that physicians should consider whether the expected benefit of Tysabri is sufficient to offset the PML risk when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML, prognosis-related considerations include the extent of neurological damage at diagnosis, the speed of immune reconstitution, and the development of IRIS. Long-term disability is common, and mortality rates remain high despite intervention. In summary, Tysabri-associated PML is a severe adverse event with a poor prognosis, typically leading to death or severe disability. Risk stratification based on anti-JCV antibody status, treatment duration, and prior immunosuppressant use is essential. Early detection through clinical monitoring and MRI, along with prompt discontinuation of Tysabri, are critical steps. The timeline for harm can extend beyond treatment cessation, necessitating continued surveillance for at least six months after discontinuation. The current warning framework, including the boxed warning and restricted distribution program, aims to mitigate risk, but the inherent severity of PML underscores the need for careful patient selection and ongoing vigilance.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the prognosis for PML after Tysabri treatment?

The prognosis for patients who develop PML after Tysabri treatment is poor. The FDA boxed warning states that PML usually leads to death or severe disability. Long-term disability is common, and mortality rates remain high despite intervention. Prognosis depends on the extent of neurological damage at diagnosis, speed of immune reconstitution, and development of IRIS.

How is severe PML treated after Tysabri?

Treatment for severe PML is primarily supportive, focusing on immune reconstitution. The main therapeutic approach is to remove Tysabri and restore immune function, often through plasma exchange or immunoadsorption to accelerate clearance of natalizumab. However, immune reconstitution can lead to IRIS, which may worsen outcomes. There is no specific antiviral therapy for JCV infection.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.